https://www.selleckchem.com/pr....oducts/pi3k-hdac-inh
To determine whether a6-day course of methylprednisolone (MP) improves outcome in patients with severe SARS-CoV‑2 (Corona Virus Disease 2019 [COVID-19]). The study was amulticentric open-label trial of COVID-19patients who were aged ≥ 18years, receiving oxygen without mechanical ventilation, and with evidence of systemic inflammatory response who were assigned to standard of care (SOC) or SOC plus intravenous MP (40 mg bid for 3 days followed by 20 mg bid for 3 days). The primary outcome was acomposite of death, admission
Like
Comment
Share
